30 results about "Cell adhesion factors" patented technology

The present relates to artificial vascular grafts, methods for manufacturing and uses for them. The grafts comprise an inner surface on which cells genetically altered to express or over-express one or more cell adhesion factors or one or more cell adhesion factors and one or more cell proliferation growth factors are seeded and cultured.

A brain-protective agent containing an NF-κB decoy. In brain diseases, the brain can be particularly effectively protected against brain disorders (for example, cerebral vasospasm following a subrachnoidal hemorrhage and apoptosis of the nerve cells following a cerebrovasucular accident or serious head injury) caused by the undesired activation of cytokines or cell adhesion factors which are regulated by NF-κB by administering the brain-protective agent containing an NF-κB decoy, i.e., acompound antadonistic specifically to a nucleic acid to which NF-κB binds.

The present invention relates to endothelial and smooth muscle cells genetically altered to express or over-express one or more cell adhesion factors. The invention further relates to cells genetically altered to express or over-express both cell proliferation growth factor(s) and cell adhesion factor(s). In addition, the present invention relates to nucleic acid constructs and nucleic acid construct systems that encode the cell adhesion and cell proliferation growth factors that are used to transfect / transform the cells so that they can express the factors.

A process for making an oligo(alkylene glycol) functionalized co-polyisocyanopeptide, wherein the process includes the steps of: i) copolymerizing a first comonomer of an oligo(alkylene glycol) functionalized isocyanopeptide grafted with a linking group and a second comonomer of a non-grafted oligo(alkylene glycol) functionalized isocyanopeptide, wherein the molar ratio between the first comonomer and the second comonomer is 1:500 and 1:30 and ii) adding a reactant of a spacer unit and a cell adhesion factor to the copolymer obtained by step i), wherein the spacer unit is represented by general formula A-L-B, wherein the linking group and group A are chosen to react and form a first coupling and the cell adhesion factor and group B are chosen to react and form a second coupling, wherein the first coupling and the second coupling are independently selected from the group consisting of alkyne-azide coupling, dibenzocyclooctyne-azide coupling, oxanorbornmadiene-based-azide couplings, vinylsulphone-thiol coupling, maleimide-thiol coupling, methyl methacrylate-thiol coupling, ether coupling, thioether coupling, biotin-strepavidin coupling, amine-carboxylic acid resulting in amides linkages, alcohol-carboxylic acid coupling resulting in esters linkages and NHS-Ester (N-Hydroxysuccinimide ester)-amine coupling and wherein group L is a linear chain segment having 10-60 bonds between atoms selected from C, N, O and S in the main chain.

An objective of the invention is to provide an adsorbent allowing purification of a blood coagulation factor or a cell adhesion factor under mild conditions, according to simple procedures, and at a low cost and safely while having a high affinity and a high resistance to deterioration, and a method for purifying the blood coagulation factor or the cell adhesion factor; a solution is to apply a polypeptide having peptide fragments represented by formula (1) as the adsorbent for the blood coagulation factor or the cell adhesion factor, and to purify the blood coagulation factor or the cell adhesion factor using the adsorbent:-(Pro-Hyp-Gly)n-Wherein, in formula (1), n is an integer from 2 to 9,000.

The invention relates to a method for photochemical cross-linking cell adhesion peptides on chitosan hydroxyl, namely a group selectively grafts the cell adhesion peptides on chitosan molecules. In particular, bifunctional photosensitive crosslinker sulfo-SANPAH is utilized to modify hydrophilic polypeptide GRGDY containing cell adhesion factors RGD on the chitosan hydroxyl to increase the water solubility and the targeting of a material, while amidogen is retained and tedious amino protection, a deprotection process and chemical toxicity caused by the same are avoided. The method adopts UV-activated photochemical cross-linking and has the advantages of mild reaction conditions and fast reaction rate, and the feature group of the crosslinker is beneficial to judging the conducting of grafting reaction. The targeted adhesion chitosan material synthesized by the method is suitable for preparing DNA and small RNA (siRNA, microRNA, shRNA, and the like.) targeted delivery systems, cell adhesion cultures, microencapsulated tissue cells for transplant, scaffolds for tissue engineering, and the like applied in the biomedical field under physiological conditions.

The invention discloses the application of osteopontin as a target molecule in regulating intestinal flora colonization; specifically: inhibiting the expression of OPN gene or blocking the combination of OPN and cell receptors, thereby increasing the number of probiotics in the intestinal tract; blocking OPN Binding to cellular receptors or inhibiting Notch signaling can enhance bacterial adhesion to intestinal epithelial cells. The present invention confirms that osteopontin affects the adhesion between cells and bacteria by inhibiting the expression of cell adhesion factors, thereby inhibiting the colonization of bacteria in the intestinal tract.

An object of the present invention is to provide a hollow-fiber membrane which does not require a coating treatment with a cell adhesion factor or surface modification by an electron beam or the like and which is capable of adhering and culturing cells, and a method for culturing cells using the hollow-fiber membrane. A hollow-fiber membrane for cell culture which is to be used as a culture substrate for adhesive cells, in which the hollow-fiber membrane includes a hydrophobic polymer and a hydrophilic polymer, the content of the hydrophilic polymer in the whole hollow-fiber membrane is more than 0% by mass and less than 1% by mass, and the content of the hydrophilic polymer on a surface of the hollow-fiber membrane is more than 0% by mass and less than 10% by mass.

The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis which comprises neuropeptide Y as an active ingredient. The neuropeptide Y according to the present invention reduces the expression of a cell adhesion factor in osteoblasts in which a Y1 receptor is present, and consequently an effect of releasing a haematopoietic stem cell from bone marrow into the blood is excellent. When a haematopoietic stem cell is released into the blood, the number of osteoclasts which induce an osteoporotic lesion by differentiation from the haematopoietic stem cell decreases, and thus progression of a bone erosion caused by osteoclasts can be prevented. Accordingly, the neuropeptide Y which is an active ingredient of the composition of the present invention is useful as a therapeutic agent for osteoporosis.